相似文献
1
Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?
Genome Med. 2010 Jul 29;2(7):45. doi: 10.1186/gm166.
2
Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease.
Cancers (Basel). 2021 Feb 12;13(4):760. doi: 10.3390/cancers13040760.
3
Genome-wide association study of prostate cancer mortality.
Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2869-76. doi: 10.1158/1055-9965.EPI-10-0601. Epub 2010 Oct 26.
4
MiRNA Profiles in Lymphoblastoid Cell Lines of Finnish Prostate Cancer Families.
PLoS One. 2015 May 28;10(5):e0127427. doi: 10.1371/journal.pone.0127427. eCollection 2015.
5
Prostate cancer risk variants are not associated with disease progression.
Prostate. 2012 Jan;72(1):30-9. doi: 10.1002/pros.21403. Epub 2011 Apr 25.
6
Genomic Analysis of Localized High-Risk Prostate Cancer Circulating Tumor Cells at the Single-Cell Level.
Cells. 2020 Aug 8;9(8):1863. doi: 10.3390/cells9081863.
7
Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression.
Prostate. 2014 Apr;74(4):372-80. doi: 10.1002/pros.22758. Epub 2013 Dec 6.
8
Inherited genetic variant predisposes to aggressive but not indolent prostate cancer.
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2136-40. doi: 10.1073/pnas.0914061107. Epub 2010 Jan 11.
9
Who bears the greatest burden of aggressive treatment of indolent prostate cancer?
Am J Med. 2015 Jun;128(6):609-16. doi: 10.1016/j.amjmed.2014.12.030. Epub 2015 Jan 30.
10
Genomic Markers in Prostate Cancer Decision Making.
Eur Urol. 2018 Apr;73(4):572-582. doi: 10.1016/j.eururo.2017.10.036. Epub 2017 Nov 10.
引用本文的文献
1
MicroRNA-4719 and microRNA-6756-5p Correlate with Castration-Resistant Prostate Cancer Progression through Interleukin-24 Regulation.
Noncoding RNA. 2019 Jan 21;5(1):10. doi: 10.3390/ncrna5010010.
2
Survivin polymorphisms and susceptibility to prostate cancer: A genetic association study and an analysis.
EXCLI J. 2018 May 18;17:479-491. doi: 10.17179/excli2018-1234. eCollection 2018.
3
PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.
Prostate. 2018 May;78(7):547-559. doi: 10.1002/pros.23499. Epub 2018 Mar 9.
4
A novel microRNA-1207-3p/FNDC1/FN1/AR regulatory pathway in prostate cancer.
RNA Dis. 2017;4(1). Epub 2017 Feb 6.
5
Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer.
BMC Urol. 2017 Jan 31;17(1):12. doi: 10.1186/s12894-017-0201-y.
6
miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin.
Exp Cell Res. 2016 Nov 1;348(2):190-200. doi: 10.1016/j.yexcr.2016.09.021. Epub 2016 Sep 29.
7
Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview.
Int Sch Res Notices. 2014 Jul 15;2014:243080. doi: 10.1155/2014/243080. eCollection 2014.
8
Association between APE1 Asp148Glu polymorphism and the risk of urinary cancers: a meta-analysis of 18 case-control studies.
Onco Targets Ther. 2016 Mar 15;9:1499-510. doi: 10.2147/OTT.S101456. eCollection 2016.
9
Gene interference strategies as a new tool for the treatment of prostate cancer.
Endocrine. 2015 Aug;49(3):588-605. doi: 10.1007/s12020-015-0629-3. Epub 2015 Jun 7.
10
CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer.
Prostate Cancer. 2014;2014:294575. doi: 10.1155/2014/294575. Epub 2014 Nov 6.
本文引用的文献
1
Inherited genetic variant predisposes to aggressive but not indolent prostate cancer.
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2136-40. doi: 10.1073/pnas.0914061107. Epub 2010 Jan 11.
2
Genome-wide association studies in cancer--current and future directions.
Carcinogenesis. 2010 Jan;31(1):111-20. doi: 10.1093/carcin/bgp273. Epub 2009 Nov 11.
3
Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3068-74. doi: 10.1158/1055-9965.EPI-09-0665.
4
Identification of a new prostate cancer susceptibility locus on chromosome 8q24.
Nat Genet. 2009 Oct;41(10):1055-7. doi: 10.1038/ng.444. Epub 2009 Sep 20.
5
Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility.
Nat Genet. 2009 Oct;41(10):1122-6. doi: 10.1038/ng.448. Epub 2009 Sep 20.
6
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.
Nat Genet. 2009 Oct;41(10):1116-21. doi: 10.1038/ng.450. Epub 2009 Sep 20.
7
Multiple loci on 8q24 associated with prostate cancer susceptibility.
Nat Genet. 2009 Oct;41(10):1058-60. doi: 10.1038/ng.452. Epub 2009 Sep 20.
8
Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
J Natl Cancer Inst. 2009 Oct 7;101(19):1325-9. doi: 10.1093/jnci/djp278. Epub 2009 Aug 31.
9
Two independent prostate cancer risk-associated Loci at 11q13.
Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1815-20. doi: 10.1158/1055-9965.EPI-08-0983.
10
Cancer statistics, 2009.
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
Zotero 插件